Aquestive Therapeutics, Inc. (AQST)
USD 2.55
(1.8%)
USD 2.55
(1.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.1 Million USD | 64.61% |
| 2022 | -42.06 Million USD | -21.3% |
| 2021 | -34.67 Million USD | 19.15% |
| 2020 | -42.89 Million USD | 18.56% |
| 2019 | -52.66 Million USD | -7.63% |
| 2018 | -48.93 Million USD | -43204.42% |
| 2017 | -113 Thousand USD | 86.66% |
| 2016 | -847 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 55 Thousand USD | 100.61% |
| 2024 Q1 | -8.95 Million USD | -129.02% |
| 2024 Q3 | -8.29 Million USD | -15172.73% |
| 2023 Q2 | -4.2 Million USD | -143.92% |
| 2023 Q1 | 9.58 Million USD | 189.45% |
| 2023 FY | -14.88 Million USD | 64.61% |
| 2023 Q4 | -3.91 Million USD | -64.54% |
| 2023 Q3 | -2.37 Million USD | 43.53% |
| 2022 FY | -42.06 Million USD | -21.3% |
| 2022 Q1 | -9.73 Million USD | 16.55% |
| 2022 Q4 | -10.71 Million USD | -21.01% |
| 2022 Q3 | -8.85 Million USD | 30.63% |
| 2022 Q2 | -12.76 Million USD | -31.05% |
| 2021 FY | -34.67 Million USD | 19.15% |
| 2021 Q1 | -8.52 Million USD | 45.51% |
| 2021 Q2 | -6.51 Million USD | 23.55% |
| 2021 Q3 | -7.96 Million USD | -22.26% |
| 2021 Q4 | -11.66 Million USD | -46.45% |
| 2020 Q4 | -15.64 Million USD | -13.53% |
| 2020 Q2 | 395 Thousand USD | 102.85% |
| 2020 FY | -42.89 Million USD | 18.56% |
| 2020 Q1 | -13.86 Million USD | -39.95% |
| 2020 Q3 | -13.78 Million USD | -3588.86% |
| 2019 Q2 | -18.68 Million USD | -42.94% |
| 2019 FY | -52.66 Million USD | -7.63% |
| 2019 Q4 | -9.9 Million USD | 9.98% |
| 2019 Q3 | -11 Million USD | 41.13% |
| 2019 Q1 | -13.07 Million USD | -5.87% |
| 2018 Q2 | -32.68 Million USD | -716.14% |
| 2018 FY | -48.93 Million USD | -43204.42% |
| 2018 Q4 | -12.34 Million USD | -34.17% |
| 2018 Q3 | -9.2 Million USD | 71.84% |
| 2018 Q1 | 5.3 Million USD | 173.11% |
| 2017 Q2 | -4.05 Million USD | -619.72% |
| 2017 Q3 | 10.42 Million USD | 356.74% |
| 2017 Q1 | 781 Thousand USD | 0.0% |
| 2017 Q4 | -7.25 Million USD | -169.63% |
| 2017 FY | -113 Thousand USD | 86.66% |
| 2016 FY | -847 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 109.045% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -500.425% |
| Embecta Corp. | 221.5 Million USD | 106.818% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 117.225% |
| PainReform Ltd. | -9.58 Million USD | -57.575% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -215.592% |
| SCYNEXIS, Inc. | 72.66 Million USD | 120.782% |
| Journey Medical Corporation | -2.07 Million USD | -628.509% |
| Safety Shot Inc | -12.18 Million USD | -23.948% |
| Alpha Teknova, Inc. | -35.56 Million USD | 57.535% |
| Bright Green Corporation | -8.89 Million USD | -69.85% |
| Procaps Group, S.A. | 38.97 Million USD | 138.75% |
| Alvotech | -354.86 Million USD | 95.744% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 132.152% |
| Cosmos Health Inc. | -21.83 Million USD | 30.824% |
| Dynavax Technologies Corporation | -37.02 Million USD | 59.215% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 90.292% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 90.525% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -215.592% |
| Theratechnologies Inc. | -10.62 Million USD | -42.11% |
| Harrow Health, Inc. | 580 Thousand USD | 2703.793% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -221.251% |
| Biofrontera Inc. | -22.67 Million USD | 33.404% |
| DURECT Corporation | -36.88 Million USD | 59.055% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -186.62% |
| Cronos Group Inc. | -81.37 Million USD | 81.442% |
| OptiNose, Inc. | -22.74 Million USD | 33.612% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 107.225% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 61.428% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 219.554% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 220.575% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -248.268% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -143.156% |
| Radius Health, Inc. | -3.92 Million USD | -284.764% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -328.21% |
| ProPhase Labs, Inc. | -21.61 Million USD | 30.125% |
| Phibro Animal Health Corporation | 53.31 Million USD | 128.326% |
| Procaps Group S.A. | 52.32 Million USD | 128.862% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -77.191% |
| Viatris Inc. | 766.2 Million USD | 101.971% |
| Rockwell Medical, Inc. | -6.67 Million USD | -126.417% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -187.438% |
| SIGA Technologies, Inc. | 83.62 Million USD | 118.06% |
| Tilray Brands, Inc. | -174.74 Million USD | 91.358% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 261.848% |
| Shineco, Inc. | -17.06 Million USD | 11.508% |
| PetIQ, Inc. | 60.01 Million USD | 125.164% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -218.828% |
| Incannex Healthcare Limited | -30.04 Million USD | 49.729% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 106.019% |
| Alimera Sciences, Inc. | -1.47 Million USD | -926.649% |
| Silver Spike Investment Corp. | 7.34 Million USD | 305.746% |
| Assertio Holdings, Inc. | -243.53 Million USD | 93.799% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -156.297% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -10.903% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 3.155% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 24.679% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 89.045% |
| Hempacco Co., Inc. | -8.81 Million USD | -71.374% |
| Talphera, Inc. | -16.88 Million USD | 10.581% |
| Alvotech | -354.86 Million USD | 95.744% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 128.252% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 104.142% |
| Currenc Group, Inc. | -6.64 Million USD | -127.242% |
| Kamada Ltd. | 10.06 Million USD | 250.06% |
| Indivior PLC | -4 Million USD | -277.55% |
| Evoke Pharma, Inc. | -7.43 Million USD | -103.233% |
| Flora Growth Corp. | -50.35 Million USD | 70.008% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 24.679% |
| Evolus, Inc. | -49.23 Million USD | 69.325% |
| HUTCHMED (China) Limited | 18.37 Million USD | 182.188% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 107.666% |
| Akanda Corp. | -10.05 Million USD | -50.248% |